FDMT FY 2024 Earnings — 4D Molecular Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FDMT4D Molecular Therapeutics, Inc.

$468M

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$37,000-99.8% YoY

Gross Profit

$37,000100.0% margin

Operating Income

-$188M-507678.4% margin

Net Income

-$161M-434778.4% margin

EPS (Diluted)

$-2.98

Cash Flow

Operating Cash Flow

-$135M

Free Cash Flow

-$138M

Stock-Based Comp.

$26M

Balance Sheet

Total Assets

$560M

Total Liabilities

$50M

Stockholders' Equity

$511M

Cash & Equivalents

$149M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$37,000	$21M	-99.8%
Gross Profit	$37,000	-$76M	+100.0%
Operating Income	-$188M	-$113M	-66.4%
Net Income	-$161M	-$101M	-59.5%